Skip to content
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Saturday, December 6, 2025
World Today News
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Copyright 2021 - All Right Reserved
Home » National Health Service » Page 2
Tag:

National Health Service

Health

GMC Social Media Rules: Should Doctors Be Regulated Online?

by Dr. Michael Lee – Health Editor June 18, 2025
written by Dr. Michael Lee – Health Editor

“`html



Navigating the Murky Waters: The Evolving Role of Doctors on Social Media

Table of Contents

  • Navigating the Murky Waters: The Evolving Role of Doctors on Social Media
    • The GMC’s Updated Guidance on Social media
    • The Fraught Landscape of Online Discourse
    • The Ethical Implications of Free Speech for Doctors
    • The Value of Dissent and critical Engagement
    • The Role of Physician Associates
      • Key Considerations for Doctors on Social Media
    • The Ancient Context of Medical Ethics and Public Discourse
    • Frequently asked Questions About Doctors and Social Media

The digital age has transformed how professionals communicate, and doctors are no exception. Once confined to hospital corridors, medical opinions now circulate globally via social media. This shift presents both opportunities and challenges,particularly concerning professional conduct and the spread of information.

The GMC’s Updated Guidance on Social media

In January 2024, the General Medical Council (GMC) released updated guidance titled “Using Social Media as a Medical Professional.” This document emphasizes maintaining professionalism, upholding patient trust, and establishing clear boundaries online. A central tenet advises against using social media to abuse, discriminate, bully, harass, or deliberately target any individual or group.

Implementing this principle raises complex questions. Where does legitimate critique end and perceived harassment begin? Is a doctor publicly challenging unsafe NHS working conditions engaging in necessary advocacy or crossing a line by targeting leadership? Are discussions about physician associates constructive criticism or professional bullying? The GMC offers limited clarity, placing doctors in ethically ambiguous territory.

Did You Know? The Federation of State Medical Boards (FSMB) offers resources on social media and professionalism for medical boards and physicians in the United States.

The Fraught Landscape of Online Discourse

Social media has become an increasingly fraught space for healthcare professionals. Platforms like X are rife with disputes among colleagues, administrators, and the GMC itself. The ongoing debate around physician associates has further inflamed tensions, with allegations ranging from misinformation and professional gatekeeping to outright bullying. While the GMC has acknowledged the increasingly toxic tone of online discourse, its response has largely been limited to expressions of concern rather than decisive action.

This situation raises a broader question: Should the GMC regulate physicians’ conduct on social media? Some argue that professionalism extends beyond clinical settings and that behavior inconsistent with medical ethics undermines public trust. Others view such oversight as overreach, contending that physicians retain the right to express personal views outside of work.

The GMC faces a delicate balancing act. Excessive enforcement risks accusations of censorship and stifling free expression. Insufficient enforcement, however, may undermine its authority as a regulator. The power of professional regulation extends beyond legal authority, including reputational impact. A doctor facing a tribunal over an online post may endure formal inquiry,public scrutiny,and reputational damage.

The Ethical Implications of Free Speech for Doctors

The debate often centers on free speech, but this simplifies a complex moral discussion. Doctors occupy a privileged epistemic position. their speech carries what can be referred to as *epistemic weight*. When doctors speak, people listen and often shape their actions in response. During the COVID-19 pandemic, doctors who spread misinformation misled millions precisely becuase they were trusted by the public.

Ethical analysis concludes that doctors, by virtue of their training and the trust they hold, bear a higher moral burden. Their views must meet a threshold of intellectual honesty and evidential rigor. Understanding the hierarchy of evidence and the scientific method is crucial.

Pro Tip: always verify information from multiple reputable sources before sharing it online, especially when it concerns health-related topics.

The Value of Dissent and critical Engagement

It’s crucial to avoid equating all nonconforming speech with danger. History is filled with figures who challenged prevailing consensus and were later vindicated, such as Ignaz Semmelweis and Gregor Mendel. What separates these figures from conspiracists is not *what* they challenged but *how* they did it. Engaging critically with evidence, welcoming scrutiny, and embracing the scientific process are vital.

If the GMC wishes to guide online professionalism without censorship, it must distinguish between these types of speech. However, even well-intentioned guidance can become irrelevant in the context of social media. Social media is not a neutral forum; its algorithms do not select for truth. Instead,it is an attention economy optimized for outrage,tribalism,and performance.

Platforms like X reward impulsiveness and reactivity over reflection and deliberation. Can professionalism be meaningfully maintained within this space, given social media’s design to fuel hyperbole and outrage?

The Role of Physician Associates

The debate surrounding physician associates (PAs) has become a particularly contentious area of discussion on social media. Concerns have been raised about the potential for misinformation and professional gatekeeping, while others have accused critics of outright bullying. This highlights the challenges in fostering constructive dialogue about evolving roles within healthcare.

Aspect Challenge potential Solution
Misinformation Rapid spread of inaccurate health information Promote evidence-based communication and critical thinking
Professional Boundaries Blurring lines between personal and professional conduct Clear guidelines and training on social media use
Online Harassment Targeting of healthcare professionals with abuse Enforcement of platform policies and support for victims

Key Considerations for Doctors on Social Media

  • Maintain Professionalism: Adhere to ethical guidelines and avoid behavior that could undermine public trust.
  • Verify Information: Ensure accuracy and reliability before sharing health-related content.
  • Engage Respectfully: Foster constructive dialogue and avoid personal attacks or inflammatory language.
  • Protect Patient Privacy: Do not share confidential patient information or discuss identifiable cases online.

What steps can individual doctors take to promote responsible social media use? How can medical organizations better support their members in navigating these challenges?

The Ancient Context of Medical Ethics and Public Discourse

The intersection of medical ethics and public discourse has a long and complex history. From the early days of medicine, physicians have grappled with the tension between their professional obligations and their right to express personal opinions.The rise of social media has amplified these challenges, creating new opportunities for doctors to engage with the public while also exposing them to increased scrutiny and potential risks.

Historically, medical societies and regulatory bodies have played a crucial role in setting standards for professional conduct and addressing ethical dilemmas. However, the rapid pace of technological change and the global reach of social media have made it increasingly difficult for these organizations to keep pace.As an inevitable result, individual doctors must take greater responsibility for their online behavior and exercise sound judgment in their interactions with the public.

Frequently asked Questions About Doctors and Social Media

What are the potential benefits of doctors using social media?
Social media can enable doctors to educate the public, share important health information, and engage in meaningful conversations about medical issues. It can also provide a platform for advocacy and allow doctors to connect with patients and colleagues.
What are the potential risks of doctors using social media?
Potential risks include the spread of misinformation, breaches of patient privacy, damage to professional reputation, and legal liability. Doctors must be aware of these risks and take steps to mitigate them.
How can doctors protect patient privacy on social media?
Doctors should avoid sharing any information that could identify a patient, including names, dates of birth, medical conditions, or treatment details. They should also be careful about posting photos or videos that could inadvertently reveal patient information.
What should doctors do if they encounter misinformation on social media?
Doctors should correct misinformation in a respectful and professional manner, providing evidence-based information to support their claims. They should also report the misinformation to the social media platform.
How can medical organizations support doctors in using social media responsibly?
Medical organizations can provide training and resources on social media ethics,develop clear guidelines for online conduct,and offer support to doctors who encounter challenges on social media.

Disclaimer: This article provides general information and should not be considered medical, legal, or financial advice. consult with a qualified professional for personalized guidance.

Share your thoughts in the comments below and help us foster a constructive dialogue about the evolving role of doctors in the digital age. Subscribe to

June 18, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

NICE Approves Ribociclib for High-Risk Early Breast Cancer

by Chief editor of world-today-news.com April 25, 2025
written by Chief editor of world-today-news.com

Ribociclib Recommended for Early Breast Cancer Treatment

LONDON — may 9, 2024 — The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug ribociclib for early breast cancer treatment in England, as the adjuvant therapy offers new hope to thousands of women. The decision, reported today, focuses on those at high risk of recurrence and marks a notable progress in cancer care by influencing the overall treatment protocol. This move, endorsed by experts, promises advances in addressing the disease.

Ribociclib Recommended for Early breast Cancer Treatment in England

The National Institute for Health and Care Excellence (NICE) has given a thumbs up to ribociclib (Kisqali, Novartis) as an adjuvant treatment for early breast cancer in patients facing a high risk of the disease returning. This decision brings new hope to thousands of women in England battling this common cancer subtype.

The Green Light for Ribociclib

NICE’s proposal specifically targets patients in England diagnosed with hormone receptor (HR)-positive, HER2-negative early breast cancer. This particular subtype represents approximately 68% of all breast cancer cases, making it the moast prevalent form of the disease.

Did you Know?

HR-positive, HER2-negative breast cancer means that the cancer cells have receptors for hormones (like estrogen and progesterone) but do not have an excess of the HER2 protein, which promotes cancer growth.

The Recurrence Challenge

Breast cancer remains the most frequently diagnosed cancer in the United kingdom, with over 56,000 new cases identified annually, according to Cancer Research UK. While the 10-year overall survival rate stands at 76%, a significant challenge persists: recurrence.

  • Approximately 30% of patients experiance a recurrence of breast cancer despite initial treatments.
  • The risk of recurrence is elevated in patients exhibiting specific clinical or pathological characteristics, including:
    • Multiple positive lymph nodes
    • Large tumor size
    • High cellular proliferation, as indicated by tumor grade or biomarkers

Ribociclib: An Expanded Role

Ribociclib had already been approved for use in combination with fulvestrant, an oestrogen receptor antagonist, for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who had previously undergone endocrine therapy. Now, its role is expanding.

According to NICE’s draft guidance, ribociclib can be used in early-stage breast cancer following surgery or other primary treatments. The oral medication should be administered alongside a luteinising hormone-releasing hormone (LHRH) agonist in premenopausal or perimenopausal women, as well as in men.

NICE estimates that this expanded use of ribociclib could benefit up to 4,000 individuals.

How Ribociclib Works

Ribociclib functions by targeting cyclin-dependent kinase (CDK) 4 and CDK 6 proteins, which play a crucial role in the growth and division of cancer cells. It is indeed administered in conjunction with an aromatase inhibitor to reduce oestrogen levels in the body.

Pro Tip

Aromatase inhibitors work by blocking the enzyme aromatase, which is responsible for producing estrogen in postmenopausal women. Since some breast cancers are fueled by estrogen, reducing its levels can help slow or stop cancer growth.

Side Effects to Consider

Like all medications, ribociclib can cause side effects. Common side effects include:

  • Fatigue
  • Anemia
  • Increased risk of infection
  • Rash
  • dizziness
  • Gastrointestinal symptoms

The Evidence is Still Developing

NICE has stated that clinical trial data suggests that ribociclib, when combined with an aromatase inhibitor, may prolong the progression-free interval compared to using an aromatase inhibitor alone. However, it is vital to note that overall survival benefits remain uncertain as the trial is still in progress.

Direct comparisons between ribociclib plus an aromatase inhibitor and abemaciclib plus endocrine therapy (the current standard treatment) have not been conducted. However, NICE notes that indirect comparisons suggest similar effectiveness.

Targeting High-Risk Cases

The treatment is specifically recommended for patients whose cancer has spread to the axillary lymph nodes. Eligibility criteria include:

  • Involvement of four or more lymph nodes, or
  • Involvement of one to three lymph nodes with a primary tumor of grade 3 or at least 5 cm in size

The appraisal committee resolute that ribociclib, when used with an aromatase inhibitor, is both clinically effective and cost-effective for this particular subgroup of patients.

Broader Use Not Yet Recommended

NICE has concluded that the available data is currently insufficient to recommend the routine use of ribociclib for all high-risk early breast cancer patients. The organization has requested additional evidence from Novartis and has scheduled a follow-up committee meeting for June.

The use of ribociclib is contingent upon the manufacturer providing the drug under the terms of a confidential agreement.

Treatment Details

The recommended dosage of ribociclib is 400 mg taken once daily for 21 consecutive days, followed by a 7-day break. This cycle is repeated for up to three years or until disease recurrence or unacceptable toxicity occurs.

When taken with an aromatase inhibitor, ribociclib should be used continuously throughout the 28-day cycle.

The list price for a 21-pack of 200 mg tablets is £983.33, excluding VAT.

Ribociclib will be made available through interim funding from the Cancer Drugs Fund and must be funded in England within 90 days of final guidance publication.

FAQ: Ribociclib for Early Breast Cancer

What is ribociclib?
Ribociclib (Kisqali) is a medication that targets CDK4 and CDK6 proteins to slow cancer cell growth.
Who is ribociclib for?
It is recommended for patients in England with HR-positive, HER2-negative early breast cancer at high risk of recurrence.
How is it taken?
It is indeed taken orally, typically with an aromatase inhibitor and, for some women and men, an LHRH agonist.
What are the common side effects?
Common side effects include fatigue,anemia,infection risk,rash,dizziness,and gastrointestinal symptoms.
Is it a cure for breast cancer?
No, it is an adjuvant treatment to reduce the risk of recurrence after initial treatments like surgery.
April 25, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Search:

Recent Posts

  • The Streaming Show That Cost A Billion Dollars For Just Two Seasons

    December 6, 2025
  • Sudanese paramilitary attack kills 50, including 33 children : NPR

    December 6, 2025
  • Title: Des Moines Buccaneers Lose 2-0 to Sioux City Musketeers

    December 6, 2025
  • Title: Augsburg vs Leverkusen: Schlotterbeck Named Captain

    December 6, 2025
  • Title: Texas Tech Linebacker Jacob Rodriguez Wins Butkus Award

    December 6, 2025

Follow Me

Follow Me
  • Live News Feeds
  • Short Important News
  • Most Important News
  • Headlinez
  • Most Recommended Web Hosting
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Copyright Notice
  • Disclaimer
  • DMCA Policy
  • EDITORIAL TEAM
  • Links
  • Privacy Policy
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com